GlycoMimetics Revenue and Competitors

Location

$194.4M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • GlycoMimetics's estimated annual revenue is currently $8.4M per year.(i)
  • GlycoMimetics received $119.0M in venture funding in March 2018.
  • GlycoMimetics's estimated revenue per employee is $168,840
  • GlycoMimetics's total funding is $194.4M.

Employee Data

  • GlycoMimetics has 50 Employees.(i)
  • GlycoMimetics grew their employee count by 0% last year.

GlycoMimetics's People

NameTitleEmail/Phone
1
VP AccountingReveal Email/Phone
2
VP, Portfolio and Project ManagementReveal Email/Phone
3
ControllerReveal Email/Phone
4
General Counsel and Company SecretaryReveal Email/Phone
5
VP, Clinical OperationsReveal Email/Phone
6
Senior Director, Corporate DevelopmentReveal Email/Phone
7
Director, Facilities, Human Resources and Office OperationsReveal Email/Phone
8
SVP and Chief Business OfficerReveal Email/Phone
9
Director, Formulation and Nonclinical DevelopmentReveal Email/Phone
10
Director Clinical Trial SuppliesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7M35-3%N/AN/A
#2
$7.2M36-5%N/AN/A
#3
$10.5M52-9%N/AN/A
#4
$344.1M17129%N/AN/A
#5
$27.5M1376%N/AN/A
#6
$107.3M5349%N/AN/A
#7
$12.9M6428%N/AN/A
#8
$31.6M1571%N/AN/A
#9
$31.4M1567%N/AN/A
#10
$11.5M5730%N/AN/A
Add Company

What Is GlycoMimetics?

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow's breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company's inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$194.4M

Total Funding

50

Number of Employees

$8.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

GlycoMimetics News

2022-04-20 - GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2022. Thu, April 28, 2022, 4:30 AM ·8 min read. In this article:.

2022-04-20 - GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot. April 28, 2022. Comments. ROCKVILLE, Md. (AP) _ GlycoMimetics Inc. (GLYC) on Thursday reported a loss of $14.7 million...

2022-04-20 - GlycoMimetics GAAP EPS of -$0.28 beats by $0.03 (NASDAQ ...

GlycoMimetics press release (NASDAQ:GLYC): Q1 GAAP EPS of -$0.28 beats by $0.03. Cash and cash equivalents of $76.5M. There was no revenue...

2019-09-08 - What's Behind the Numbers For GlycoMimetics, Inc ...

The Price to Book ratio for GlycoMimetics, Inc. NasdaqGM:GLYC is 0.841807. The Price to book ratio is the current share price of a company ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.6M509%N/A
#2
$5.8M500%N/A
#3
$7.5M504%N/A
#4
$5.8M5011%N/A
#5
$11.7M516%N/A

GlycoMimetics Funding

DateAmountRoundLead InvestorsReference
2003-05-23$4.3M1stNew Enterprise AssociatesArticle
2004-08-06$9.6MAAlliance Technology Ventures, Anthem Capital ManagementArticle
2006-06-26$15.4MUndisclosedNew Enterprise AssociatesArticle
2009-10-21$38.0MUndisclosedGenzyme Ventures, New Enterprise AssociatesArticle
2016-06-20$18.6MUndisclosedJefferies LLCArticle
2017-05-25$92.6MUndisclosedJefferies LLCArticle
2018-03-21$119.0MUndisclosedJefferiesArticle